{"commentary":{"count":92,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":43,"youtube":31,"podcast":15,"x_video":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05425940\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"STELLAR-303","nct_id":"NCT05425940","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stellar-303-nct05425940. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"STELLAR-303","arms":[{"description":"Participants with mCRC will receive XL092 + atezolizumab.","label":"XL092 + Atezolizumab","type":"EXPERIMENTAL"},{"description":"Participants with mCRC will receive active comparator of regorafenib.","label":"Regorafenib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-01-31","type":"ESTIMATED"},"conditions":["Colorectal Cancer"],"enrollment":{"count":901,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"XL092","type":"DRUG"},{"name":"Atezolizumab","type":"DRUG"},{"name":"Regorafenib","type":"DRUG"}],"last_update":"2026-07-17","lead_sponsor":"Exelixis","official_title":"A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized Participants","timeFrame":"Up to 32 months"},{"measure":"Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in Randomized Non-Liver Metastases (NLM) Participants","timeFrame":"Up to 32 months"}],"references":[{"citation":"Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E, Fakih M, Asghari G, So J, Stein A, Dubreuil O, Bodnar L, He CS, Wang G, Smith R, Eng C, Saeed A; STELLAR-303 study investigators. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet. 2025 Nov 15;406(10517):2360-2370. doi: 10.1016/S0140-6736(25)02025-2. Epub 2025 Oct 20.","pmid":"41130252","type":"DERIVED"},{"citation":"Saeed A, Tabernero J, Parikh A, Van den Eynde M, Karthaus M, Gerlinger M, Wang Z, Wang G, Smith R, Hecht JR. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer. Future Oncol. 2024;20(24):1733-1743. doi: 10.1080/14796694.2024.2352276. Epub 2024 Jul 23.","pmid":"39041200","type":"DERIVED"}],"start_date":{"date":"2022-09-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT05425940"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stellar-303-nct05425940"}